{"id":10248,"date":"2019-03-22T16:36:32","date_gmt":"2019-03-22T16:36:32","guid":{"rendered":"https:\/\/futurehealthbiobank.com\/ae-en-new\/?p=10248"},"modified":"2019-04-26T13:08:58","modified_gmt":"2019-04-26T12:08:58","slug":"a-joint-statement-from-the-industry-leaders-on-grossly-misleading-statements-made-by-cells4life-regarding-their-toticyte-processing-method","status":"publish","type":"post","link":"https:\/\/futurehealthbiobank.com\/ae-en\/blog\/a-joint-statement-from-the-industry-leaders-on-grossly-misleading-statements-made-by-cells4life-regarding-their-toticyte-processing-method\/","title":{"rendered":"A JOINT STATEMENT FROM THE INDUSTRY LEADERS ON STATEMENTS MADE BY CELLS4LIFE REGARDING THEIR TOTICYTE PROCESSING METHOD"},"content":{"rendered":"
\n

\"\"
\n<\/p>\n

C4L states that their in-house Toticyte processing method provides 3 times more stem cells from the umbilical cord than any other cord blood processing method that they have tested, including all systems currently used in the UK.<\/p>\n

As the majority of public and private cord blood banks use Sepax\u2122, AXP\u2122 or Macopress\u2122 processing technologies, we consider that the statement propagated by C4L implies that respected establishments, including the NHSBT, Anthony Nolan Trust and transplant centres worldwide, are working with inferior and inconsistent low viable stem cell recovery levels.<\/p>\n

Throughout the world, many thousands of patients have been successfully transplanted using cord blood units processed using Sepax\u2122, AXP\u2122 or Macopress\u2122. In clinical and scientific literature, viable CD34+ post-thaw recovery levels of >70% are cited as acceptable and achievable for clinical use.<\/p>\n

FHB and SCI undertake regular auditing of cord blood post-thaw viable stem cell recovery following processing using established and accepted technologies. This data for each organisation must undergo Human Tissue Authority (HTA) scrutiny as part of the inspection process relating to the Human Application Licence. Losses of 60-70% following cryopreservation would be unacceptable.<\/p>\n

Both FHB and SCI are able to demonstrate an average CD34+ stem cell recovery rate above 70%. The comparative figures presented by C4L have been generated as a result of \u201cin house\u201d investigations and present a significantly skewed perspective on post-thaw viable CD34+ recovery following processing using by our technologies.<\/p>\n

It is the view of both FHB and SCI that they achieve notably higher post-thaw CD34+ stem cells counts than C4L do using their Toticyte method (based on data published by C4L).<\/strong><\/p>\n

\n
\n

\"\"<\/p>\n<\/div>\n

\n

FHB and SCI would like to point out that no sample processed using C4L\u2019s Toticyte method has ever been used in a clinical application. In contrast, SCI and FHB have released many samples for successful clinical use using their proven sample processing technologies. The point being that currently C4L has no track record in relation to clinical use.<\/p>\n<\/div>\n<\/div>\n

\n

Chris Bond Managing Director, Future Health Biobank<\/strong> and Shamshad Ahmed CEO, Smart Cells International<\/strong><\/p>\n

About Future Health Biobank (FHB) and Smart Cells International (SCI)<\/strong><\/p>\n

FHB and SCI are pioneers and experts in the private stem cell industry being the first two cord blood banks to be established in the UK nearly 20 years ago.<\/p>\n

Between them, they have processed and stored more than 150,000 cord blood units from over 75 countries worldwide within their state-of-the-art UK laboratories. Today, they process and store between them, more than two thirds of all private cord blood units within the UK.<\/p>\n

Both companies use industry leading, proven processing technologies and have released many cord blood units for successful clinical applications.<\/p>\n<\/div>\n

\n